Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure^*

References

• Cheah CY, Campbell BA, Seymour JF. Primary breast lymphoma. Cancer Treat Rev. 2014;40:900–908.
   PubMed Web of Science ®Google Scholar
• Caon J, Wai ES, Hart J, et al. treatment and outcomes of primary breast lymphoma. Clin Breast Cancer. 2012;12:412–419.
   PubMed Web of Science ®Google Scholar
• Aviv A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol. 2013;24:2236–2244.
   PubMed Web of Science ®Google Scholar
• Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2008;19:233–241.
   PubMed Web of Science ®Google Scholar
• Talwalkar SS, Miranda RN, Valbuena JR, et al. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol. 2008;32:1299–1309.
   PubMed Web of Science ®Google Scholar
• Ha CS, Dubey P, Goyal LK, et al. Localized primary non-Hodgkin lymphoma of the breast. Am J Clin Oncol. 1998;21:376–380.
   PubMed Web of Science ®Google Scholar
• Jennings WC, Baker RS, Murray SS, et al. Primary breast lymphoma: the role of mastectomy and the importance of lymph node status. Ann Surg. 2007;245:784–789.
   PubMed Web of Science ®Google Scholar
• Kuper-Hommel MJ, Snijder S, Janssen-Heijnen ML, et al. Treatment and survival of 38 female breast lymphomas: a population-based study with clinical and pathological reviews. Ann Hematol. 2003;82:397–404.
   PubMed Web of Science ®Google Scholar
• Avenia N, Sanguinetti A, Cirocchi R, et al. Primary breast lymphomas: a multicentric experience. World J Surg Oncol. 2010;8:53.
   PubMed Web of Science ®Google Scholar
• Hosein PJ, Maragulia JC, Salzberg MP, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014;165:358–363.
   PubMed Web of Science ®Google Scholar
• Aviles A, Delgado S, Nambo MJ, et al. Primary breast lymphoma: results of a controlled clinical trial. Oncology. 2005;69:256–260.
   PubMed Web of Science ®Google Scholar
• Thomas A, Link BK, Altekruse S, et al. Primary breast lymphoma in the United States: 1975–2013. J Natl Cancer Inst. 2017;109(6):djw294.
   PubMedGoogle Scholar
• Maurer MJ, Ghesguieres H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066–1073.
   PubMed Web of Science ®Google Scholar
• Jakobsen LH, Bogsted M, Brown PN, et al. Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study. J Clin Oncol. 2017;35:778–784.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• IBM. Corp. Released. 2013. IBM SPSS statistics for windows, version 22.0. Armonk, NY: IBM Corp.
   Google Scholar
• DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20:4643–4648.
   PubMed Web of Science ®Google Scholar
• Stephens DM, Li H, LeBlanc ML, et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736. J Clin Oncol. 2016;34:2997–3004.
   PubMed Web of Science ®Google Scholar
• Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86–92.
   PubMed Web of Science ®Google Scholar
• Yalahom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92:11–31.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Solomon B, Wolf MM, et al. Primary large-cell non-Hodgkin’s lymphoma of the testis. A retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma. 2001;2:109–115.
   PubMedGoogle Scholar
• Zucca E, Conconi A, Mughal T, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21:20–27.
   PubMed Web of Science ®Google Scholar
• Ho JC, Dabaja BS, Milgrom SA, et al. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017;58:2833–2844.
   PubMed Web of Science ®Google Scholar
• Trudeau M, Shepherd FA, Blackstein ME, et al. Intraocular lymphoma: report of three cases and review of the literature. Am J Clin Oncol. 1988;11:126–130.
   PubMed Web of Science ®Google Scholar
• Peterson K, Gordon KB, Heinemann MH, et al. The clinical spectrum of ocular lymphoma. Cancer. 1993;72:843–849.
   PubMed Web of Science ®Google Scholar
• Validire P, Capovilla M, Asselain B, et al. Primary breast non-Hodgkin’s lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors. Am J Hematol. 2009;84:133–139.
   PubMed Web of Science ®Google Scholar
• Aviles A, Castaneda C, Neri N, et al. Rituximab and dose dense chemotherapy in primary breast lymphoma. Haematologica. 2007;92:1147–1148.
   PubMedGoogle Scholar
• Guirguis HR, Cheung MC, Mahrous M, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol. 2012;159:39–49.
   PubMed Web of Science ®Google Scholar
• International Extranodal Lymphoma Study Group: Ongoing Trials. [cited 2017 Nov 10]. http://www.ielsg.org/trialson.html.
   Google Scholar
• Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131:174–181.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Herbert KE, O’Rourke K, et al. A multicenter retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111:1072–1079.
   PubMed Web of Science ®Google Scholar
• Peñalver FJ, Sancho JM, de la Fuente A, et al. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica. 2018;102:235–245.
   Web of Science ®Google Scholar
• Bierman PJ, Villanueva ML, Armitage JO. Diffuse large B-cell lymphoma of the breast: a distinct entity? Ann Oncol. 2008;19:201–202.
   PubMed Web of Science ®Google Scholar
• Aviles A. Breast lymphoma. Ann Oncol. 2008;19:1360.
   PubMed Web of Science ®Google Scholar